Chair and Presenter, Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Jia Ruan, MD, PhD, and Paolo Strati, MD, discuss aggressive lymphoma in this CME/MOC activity titled “Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YVY865. CME/MOC credit will be available until January 8, 2024.
The Next Phase of Targeted Therapy in MCL and DLBCL
Теги
Toby A Eyre MBChB DipMedEd MRCP FRCPath MDJia Ruan MD PhDPaolo Strati MDCMEMOCmededoncologyhematologylymphomaaggressive lymphomaMCLDLBCLBTKicovalent BTKinon-covalent BTKiibrutinibacalabrutinibzanubrutinibnemtabrutinibpirtobrutinibCAR-Tbrexucabtagene autoleucelBTKi intolerancebispecific antibodiesimmunotherapyglofitamabbendamustinerituximablenalidomideALRvenetoclaxnon-GCB DLBCLloncastuximab tesirinepolatuzumab vedotinASH 2022
